AstraZeneca (AZN) Aktienübersicht
AstraZeneca PLC, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entdeckung, Entwicklung, Herstellung und Vermarktung von verschreibungspflichtigen Medikamenten. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 5/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 3/6 |
Belohnungen
Risikoanalyse
AZN Community Fair Values
Create NarrativeSee what 300 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AstraZeneca PLC Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | UK£125.94 |
| 52-Wochen-Hoch | UK£157.32 |
| 52-Wochen-Tief | UK£101.78 |
| Beta | 0.22 |
| 1 Monat Veränderung | -4.84% |
| 3 Monate Veränderung | -15.77% |
| 1 Jahr Veränderung | 22.34% |
| 3 Jahre Veränderung | 16.94% |
| 5 Jahre Veränderung | 48.51% |
| Veränderung seit IPO | 1,796.69% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 16
AZN: Trial Setbacks And Oncology Deals Will Shape Medium Term Credibility
AstraZeneca's updated analyst price targets show a modest reset lower, with recent research pointing to greater uncertainty around medium term revenue catalysts and mixed trial outcomes, even as some analysts continue to highlight areas of support within the broader pipeline and existing portfolio. Analyst Commentary Recent research on AstraZeneca highlights a mix of caution and support, with several firms revisiting their models after the CARDIO TTRansform outcome and reassessing how much risk investors are taking on around the medium term growth story.
Narrative-Update • Jul 02
AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.Recent updates
Narrative-Update • Jul 16
AZN: Trial Setbacks And Oncology Deals Will Shape Medium Term Credibility
AstraZeneca's updated analyst price targets show a modest reset lower, with recent research pointing to greater uncertainty around medium term revenue catalysts and mixed trial outcomes, even as some analysts continue to highlight areas of support within the broader pipeline and existing portfolio. Analyst Commentary Recent research on AstraZeneca highlights a mix of caution and support, with several firms revisiting their models after the CARDIO TTRansform outcome and reassessing how much risk investors are taking on around the medium term growth story.Narrative-Update • Jul 02
AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.Analyseartikel • Jun 19
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback
AstraZeneca (LSE:AZN) is back in focus after recent share price pressure, with the stock down about 5% over the past month and past 3 months. This has prompted investors to reassess its long term profile. See our latest analysis for AstraZeneca. Despite the recent share price decline, with the stock down 5.3% on a 90 day share price return basis and currently trading at £131.54, AstraZeneca still shows a 73.7% total shareholder return over five years. This suggests long term holders have seen...
Narrative-Update • Jun 18
AZN: New Approvals And AI Use Will Support Future Repricing
The latest narrative update on AstraZeneca reflects a modest trimming of the analyst fair value estimate to £164.85, as analysts factor in updated revenue growth and profit margin assumptions following recent price target increases and ongoing commentary around the company’s drug pipeline and regulatory outcomes. Analyst Commentary Recent Street research around AstraZeneca centers on how regulators and pricing decisions may affect the company’s growth options, as well as how advisory outcomes could influence execution risk in parts of its pipeline.Narrative-Update • Jun 03
AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing
Analysts have lifted their AstraZeneca price targets by up to £1,000 per share, pointing to updated valuation work that reflects Baxfendy's FDA approval, recent price target revisions from several banks, and slight tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research around AstraZeneca clusters into two camps, with some analysts leaning more optimistic after Baxfendy's approval and a series of price target moves, while others highlight execution and regulatory questions that could affect how those targets are met.Narrative-Update • Apr 29
AZN: Pipeline Readouts And 2H26 Catalyst Path Will Drive Bullish Repricing
AstraZeneca's analyst price targets have been raised in recent research, with moves such as Guggenheim's lift to £160.00 and Citi's and Morgan Stanley's increases in their London based targets, as analysts point to refreshed models, updated earnings views and a more constructive stance on the pipeline. Analyst Commentary Recent research around AstraZeneca centres on refreshed valuation work, updated earnings paths and how the pipeline feeds into longer term growth expectations.Narrative-Update • Apr 15
AZN: Updated Oncology Pipeline Outlook Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets, with several recent moves in the £500 to £1,000 range. They cite stronger confidence in the earnings outlook and pipeline after updated models and conference follow ups.Narrative-Update • Apr 01
AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations
AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research. Analyst Commentary Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events.Narrative-Update • Mar 18
AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating
Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.Narrative-Update • Mar 03
AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook
The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.Narrative-Update • Feb 17
AZN: Elevated Margin Assumptions Will Face Pressure From Pipeline And Competition Risks
Narrative Update: AstraZeneca Analyst Price Target Shift Analysts have raised their fair value estimate for AstraZeneca from £108.53 to £117.29, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple, supported by recent price target increases and fresh bullish coverage across several banks. Analyst Commentary Recent Street research on AstraZeneca has leaned positive, with several banks adjusting fair value estimates and starting coverage with supportive views.Narrative-Update • Feb 03
AZN: Oncology Pipeline And Manufacturing Investments Will Shape Balanced Long-Term Outlook
Analysts have lifted their AstraZeneca fair value estimate to £152.79 from £150.26, reflecting higher price targets from several firms and updated views on the company’s revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on AstraZeneca has been active, with several bullish analysts lifting price targets and initiating positive coverage.Narrative-Update • Jan 20
AZN: Oncology Pipeline And 2030 Sales Ambition Will Support Re Rating
Narrative Update The analyst price target for AstraZeneca has been nudged higher to reflect a fair value estimate of £182.81 per share, with analysts pointing to supportive Street research that includes recent target upgrades from Deutsche Bank and Barclays, as well as constructive commentary on oncology and the broader biopharma pipeline. Analyst Commentary Recent Street research reflects a cluster of bullish analysts lifting price targets on AstraZeneca, with several pointing to oncology and the broader biopharma pipeline as key parts of their constructive view.Narrative-Update • Jan 06
AZN: Oncology And Biopharma Execution Will Offset Patent Pressure Concerns
AstraZeneca's implied fair value has shifted from £173.72 to £182.32 as analysts weigh stronger confidence in oncology and broader biopharma sales potential against concerns about approaching patent pressures and a less certain pipeline in breast cancer. Analyst Commentary Recent research shows a split in views, but bullish analysts see room for AstraZeneca's valuation to reflect stronger confidence in oncology and biopharma execution, even as others flag upcoming patent risks and breast cancer pipeline uncertainty.Narrative-Update • Dec 14
AZN: Oncology Execution And US Manufacturing Expansion Will Drive Long-Term Upside Potential
Analysts have nudged their fair value estimate for AstraZeneca higher to approximately $150.26 from about $146.44, reflecting confidence that the company can deliver on its long term, oncology driven growth ambitions despite mixed views on patent risk and pipeline momentum. Analyst Commentary Recent Street research highlights a sharp divergence in views on AstraZeneca, with some bullish analysts emphasizing the durability of its oncology growth engine and others warning that the valuation already discounts too optimistic a pipeline and patent outcome.Narrative-Update • Nov 28
AZN: Oncology Pipeline Execution And Patent Expiry Risks Will Define Long-Term Prospects
AstraZeneca's analyst price target was revised slightly higher from £145.43 to £146.44, as analysts cite optimism around the company's oncology franchises and biopharma pipeline. Some remain cautious given upcoming patent pressures and mixed views on pipeline outlook.Narrative-Update • Nov 14
AZN: Oncology Pipeline Momentum And Patent Pressures Will Shape Outlook Amid Policy Changes
AstraZeneca's analyst price target has inched higher from $144.38 to $145.43, as analysts cite ongoing strength in its oncology franchises and biopharma pipeline, along with improved margin expectations. Analyst Commentary Recent Street research on AstraZeneca reflects a wide range of perspectives on the company's outlook, with both bullish and bearish analysts voicing key points of emphasis around valuation, pipeline potential, and execution risks.Analyseartikel • Nov 13
AstraZeneca's (LON:AZN) Performance Is Even Better Than Its Earnings Suggest
AstraZeneca PLC's ( LON:AZN ) strong earnings report was rewarded with a positive stock price move. We have done some...Narrative-Update • Oct 31
AZN: In-Market Oncology And U.S. Drug Pricing Will Shape Long-Term Performance
AstraZeneca's analyst-derived fair value has been raised to $144.38 per share from $140.96. This reflects modest increases in pipeline confidence and anticipated revenue growth, as noted by analysts in recent research updates.Aktionärsrenditen
| AZN | GB Pharmaceuticals | GB Markt | |
|---|---|---|---|
| 7D | -1.9% | -1.4% | 1.0% |
| 1Y | 22.3% | 22.9% | 17.2% |
Rendite im Vergleich zur Industrie: AZN wie die Branche UK Pharmaceuticals , die im vergangenen Jahr eine Rendite von 22.9 erzielte.
Rendite vs. Markt: AZN übertraf den Markt UK, der im vergangenen Jahr eine Rendite von 17.2 erzielte.
Preisvolatilität
| AZN volatility | |
|---|---|
| AZN Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.7% |
Stabiler Aktienkurs: AZN hatte in den letzten 3 Monaten im Vergleich zum UK -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: AZNDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1992 | 96,100 | Pascal Claude Soriot | www.astrazeneca.com |
AstraZeneca PLC, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entdeckung, Entwicklung, Herstellung und Vermarktung von verschreibungspflichtigen Medikamenten. Das Unternehmen bietet Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, und Symbicort pMDI. Es bietet auch Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium und andere Medikamente.
AstraZeneca PLC's Grundlagenzusammenfassung
| AZN grundlegende Statistiken | |
|---|---|
| Marktanteil | UK£195.34b |
| Gewinn(TTM) | UK£7.72b |
| Umsatz(TTM) | UK£44.91b |
25.3x
Kurs-Gewinn-Verhältnis 4.3x
Kurs-Umsatz-VerhältnisIst AZN zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| AZN Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$60.44b |
| Kosten der Einnahmen | US$11.18b |
| Bruttogewinn | US$49.26b |
| Sonstige Ausgaben | US$38.87b |
| Gewinn | US$10.39b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Jul 27, 2026
| Gewinn per Aktie (EPS) | 6.70 |
| Bruttomarge | 81.51% |
| Nettogewinnspanne | 17.19% |
| Schulden/Eigenkapital-Verhältnis | 67.8% |
Wie hat sich AZN auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
1.8%
Aktuelle Dividendenrendite48%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/19 11:25 |
| Aktienkurs zum Tagesende | 2026/07/17 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
AstraZeneca PLC wird von 56 Analysten beobachtet. 24 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |